Give the body a blueprint to heal itself.
Dimension Inx is a clinical stage advanced therapies company. We develop therapeutic products that restore organ function and offer curative solutions to patients.
Cells alone are not enough.
The surrounding environment plays a key role in directing cell behavior. Our unique approach to biomaterial design focuses on the entire cell/tissue environment. We provide the three-dimensional blueprint that directs cells to behave as intended and restore critical functions.
Tissue Therapeutics represent a new era of medicine, where cells and biomaterials are combined to become the next generation of therapeutics – where 3D printing, material science, and biology converge to restore, repair, replace, or augment biological functions in the body.
Unlock the curative potential of cell therapies.
Cell functionality requires complex nano-, micro-, and macro-interactions with surrounding tissues. Our biomaterials provide those critical interactions. When cells engraft well with surrounding tissue, they can behave more like native tissue and perform better for longer.
We create “tissue-like” environments that promote rapid vascular engraftment and integration with surrounding tissue to create a more durable therapeutic response.
CMFlex: Biomaterials Platform Validation
De-risking our biomaterials platform and showcasing our ability to commercialize products, CMFlex is the first FDA-cleared 3D-printed regenerative bone graft for facial reconstruction. When implanted, it creates an environment that directs a series of biological responses, leading to exceptional bone regeneration – without adding cells or growth factors.
Learn more at cmflex3d.com.
Tissue Therapeutics Pipeline
We combine cells and biomaterials in a three-dimensional matrix designed to overcome key challenges in cell therapy. Our development efforts are focused today on advancing lead candidates for liver disease and type 1 diabetes. These indications are particularly suitable for our cell+biomaterials approach, as traditional delivery approaches have not achieved sustained restoration of function.
Technology
A fundamentally different approach for a longer, more durable therapeutic response
Dimension develops therapies that bring cells and biomaterials together to create the optimal environment for restoring organ function - curative for patients.
Our biomaterials platform combines materials science, advanced engineering, 3D-printing, and advanced digital manufacturing to optimize the 3D blueprint for cells.
Team
Leadership
Caralynn Nowinski Collens, M.D.
Co-founder & CEO
Ramille Shah, Ph.D.
Co-founder, Head of R&D, and CSO
Board
Larry Weinstein
SVP, Manufacturing & Quality Operations
Rima Chakrabarti, M.D.
Director
Andy Christensen
Advisors
Chris Ehrlich
Bart Kus, Ph.D.
SVP, Business Development
Cole Johnson, Ph.D.
VP, Strategic Growth
Ritu Shah
Head of Organizational Development
Amy Kruse, Ph.D.
Director
Derek Steinbacher, D.M.D., M.D., FACS, FRCS (Ed)
Ayush Jain
Observer
Travis Manasco, M.D.
Observer
Doris Taylor, Ph.D., DSc (H), FACC, FAHA
Lonnie Shea, Ph.D.
Salman Khetani, Ph.D.
Caralynn Nowinski Collens, M.D.
Director
Ramille Shah, Ph.D.
Director
Recent Press
October 12, 2022
August 27, 2024
July 23, 2024
October 4, 2023
February 2, 2023
February 1, 2023
February 21, 2024
Interested in joining our team?
We believe that innovation drives disruptive and unexpected solutions. In that spirit, we take risks, pushing boundaries but always guided by science. We seek out and have deep respect for unique expertise and diverse perspectives.
We collaborate to inspire and create solutions that matter. We use our experience, expertise, and creativity to create value. We are good partners who do what we say we are going to do.
We seek to build our team with similarly driven individuals.